Lidia Oostvogels

4.5k total citations
40 papers, 1.2k citations indexed

About

Lidia Oostvogels is a scholar working on Epidemiology, Dermatology and Virology. According to data from OpenAlex, Lidia Oostvogels has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 10 papers in Dermatology and 9 papers in Virology. Recurrent topics in Lidia Oostvogels's work include Herpesvirus Infections and Treatments (26 papers), Acne and Rosacea Treatments and Effects (9 papers) and Animal Virus Infections Studies (7 papers). Lidia Oostvogels is often cited by papers focused on Herpesvirus Infections and Treatments (26 papers), Acne and Rosacea Treatments and Effects (9 papers) and Animal Virus Infections Studies (7 papers). Lidia Oostvogels collaborates with scholars based in Belgium, United States and Germany. Lidia Oostvogels's co-authors include Thomas C. Heineman, Himal Lal, Desmond Curran, Geert Leroux‐Roels, Laura Cámpora, Oliver Schönborn‐Kellenberger, Lisa Walz, Isabel Leroux‐Roels, Frank von Sonnenburg and Cassandra Aldrich and has published in prestigious journals such as The Journal of Infectious Diseases, Journal of the American Geriatrics Society and Frontiers in Immunology.

In The Last Decade

Lidia Oostvogels

40 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lidia Oostvogels Belgium 21 733 353 225 195 166 40 1.2k
Olivier Godeaux Belgium 10 1.1k 1.5× 245 0.7× 234 1.0× 166 0.9× 116 0.7× 20 1.4k
Jon E. Stek United States 23 1.2k 1.6× 321 0.9× 286 1.3× 228 1.2× 120 0.7× 49 1.5k
Himal Lal Belgium 14 1.3k 1.8× 215 0.6× 376 1.7× 265 1.4× 181 1.1× 23 1.6k
Atsuko Hata Japan 16 881 1.2× 199 0.6× 134 0.6× 81 0.4× 43 0.3× 42 1.2k
Franco Gargiulo Italy 16 371 0.5× 301 0.9× 71 0.3× 128 0.7× 26 0.2× 54 784
Robin Saltzman United States 15 1.1k 1.6× 242 0.7× 167 0.7× 162 0.8× 18 0.1× 18 1.4k
David H. Shepp United States 20 1.4k 1.9× 408 1.2× 223 1.0× 332 1.7× 20 0.1× 39 1.8k
Laura Cámpora Belgium 7 574 0.8× 189 0.5× 91 0.4× 55 0.3× 53 0.3× 12 659
Arvydas Ambrozaitis Lithuania 15 512 0.7× 215 0.6× 70 0.3× 68 0.3× 16 0.1× 43 847
Victor H. Ferreira Canada 20 437 0.6× 546 1.5× 21 0.1× 186 1.0× 85 0.5× 59 1.3k

Countries citing papers authored by Lidia Oostvogels

Since Specialization
Citations

This map shows the geographic impact of Lidia Oostvogels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lidia Oostvogels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lidia Oostvogels more than expected).

Fields of papers citing papers by Lidia Oostvogels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lidia Oostvogels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lidia Oostvogels. The network helps show where Lidia Oostvogels may publish in the future.

Co-authorship network of co-authors of Lidia Oostvogels

This figure shows the co-authorship network connecting the top 25 collaborators of Lidia Oostvogels. A scholar is included among the top collaborators of Lidia Oostvogels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lidia Oostvogels. Lidia Oostvogels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wolz, Olaf‐Oliver, Dominik Vahrenhorst, Gianluca Quintini, et al.. (2024). Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity. Vaccines. 12(4). 388–388. 1 indexed citations
2.
Valentin, Antonio, Cristina Bergamaschi, Margherita Rosati, et al.. (2022). Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. Frontiers in Immunology. 13. 945706–945706. 20 indexed citations
3.
4.
Aldrich, Cassandra, Isabel Leroux‐Roels, Oliver Schönborn‐Kellenberger, et al.. (2021). Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine. 39(8). 1310–1318. 139 indexed citations
5.
Colindres, Rómulo E., Valentine Wascotte, Caroline Hervé, et al.. (2020). Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human Vaccines & Immunotherapeutics. 16(11). 2628–2633. 27 indexed citations
6.
Curran, Desmond, Melissa K. Andrew, Myron J. Levin, et al.. (2019). Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Human Vaccines & Immunotherapeutics. 15(12). 2960–2968. 8 indexed citations
7.
Strezova, Ana, Himal Lal, Laura Cámpora, et al.. (2019). The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. Vaccine. 37(39). 5877–5885. 21 indexed citations
8.
Colindres, Rómulo E., Valentine Wascotte, Caroline Hervé, et al.. (2019). 2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1. Open Forum Infectious Diseases. 6(Supplement_2). S981–S982. 1 indexed citations
9.
Lecrenier, Nicolas, Rómulo E. Colindres, Desmond Curran, et al.. (2018). Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Review of Vaccines. 17(7). 619–634. 76 indexed citations
10.
Curran, Desmond, Lidia Oostvogels, Thomas C. Heineman, et al.. (2018). Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. The Journals of Gerontology Series A. 74(8). 1231–1238. 43 indexed citations
11.
Curran, Desmond, Desirée Van Oorschot, Lijoy Varghese, et al.. (2017). Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Human Vaccines & Immunotherapeutics. 13(10). 2213–2221. 39 indexed citations
12.
Burnett, Heather, Ashleigh McGirr, Desmond Curran, et al.. (2017). Vaccines for Herpes Zoster: A Systematic Review of Randomized Controlled Trials In Adults ≥50 Years of Age. Value in Health. 20(9). A780–A780. 2 indexed citations
13.
Cámpora, Laura, Martine Douha, Thomas C. Heineman, et al.. (2017). Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. The Journal of Infectious Diseases. 216(11). 1343–1351. 52 indexed citations
14.
McGirr, Ashleigh, Heather Burnett, Desmond Curran, et al.. (2017). Network Meta-Analysis In The Evaluation of Vaccines. Value in Health. 20(9). A777–A777. 1 indexed citations
15.
Dewé, Walthère, et al.. (2015). A multi-criteria decision making approach to identify a vaccine formulation. Journal of Biopharmaceutical Statistics. 26(2). 352–364. 4 indexed citations
16.
Couch, Robert B., José M. Bayas, Innocent N. Mbawuike, et al.. (2014). Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infectious Diseases. 14(1). 425–425. 28 indexed citations
17.
Essen, Gerrit A. van, Jiřı́ Beran, Jeanne‐Marie Devaster, et al.. (2014). Influenza symptoms and their impact on elderly adults: randomised trial of AS03‐adjuvanted or non‐adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza and Other Respiratory Viruses. 8(4). 452–462. 22 indexed citations
18.
Berkowitz, Elchonon M., Graeme Moyle, Hans‐Jürgen Stellbrink, et al.. (2014). Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study. The Journal of Infectious Diseases. 211(8). 1279–1287. 144 indexed citations
19.
Durviaux, Serge, John J. Treanor, Jiřı́ Beran, et al.. (2013). Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial. Clinical and Vaccine Immunology. 21(3). 271–279. 5 indexed citations
20.
Phua, Kong Boo, Filip Lim, YL Lau, et al.. (2009). Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study. Vaccine. 27(43). 5936–5941. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Godeaux Breakdown of academic impact, for papers by Jon E. Stek Breakdown of academic impact, for papers by Himal Lal Breakdown of academic impact, for papers by Atsuko Hata Breakdown of academic impact, for papers by Franco Gargiulo Breakdown of academic impact, for papers by Robin Saltzman Breakdown of academic impact, for papers by David H. Shepp Breakdown of academic impact, for papers by Laura Cámpora Breakdown of academic impact, for papers by Arvydas Ambrozaitis Breakdown of academic impact, for papers by Victor H. Ferreira
Rankless by CCL
2026